Skip Nav Destination
1-20 of 139
Shusuke Uekusa, Yuki Hanai, Shinobu Hirayama, Takuya Yokoo, Tetsuya Hasegawa, Kohei Shimoyama, Ayumu Kusano, Kenji Nishizawa, Takahiro Matsumoto, Kazuhiro Matsuo
Pharmacology (2023) 108 (5): 444–450.
Published Online: 02 August 2023
... to in the content or advertisements. 2023 Piperacillin-tazobactam Pharmacokinetics Nephrotoxicity Therapeutic drug monitoring Vancomycin Vancomycin hydrochloride (VCM) is one of the frequently used antibacterial agents for invasive, methicillin-resistant Staphylococcus aureus infections. VCM...
Pharmacology (2022) 107 (9-10): 446–463.
Published Online: 13 June 2022
..., redirected cytotoxicity, CAR T cell amplification, active migration, and long-term persistence and immunological memory. Here, we discuss pharmaceutical aspects, the regulatory requirements for CAR T cell manufacturing, and how CAR T cell pharmacokinetics are connected with the clinical outcome. Key Messages...
Vanessa Gonzalez-Covarrubias, Héctor Sánchez-Ibarra, Karla Lozano-Gonzalez, Sergio Villicaña, Tomas Texis, Mauricio Rodríguez-Dorantes, Sergio Cortés-Ramírez, Fernando Lavalle-Gonzalez, Xavier Soberón, Hugo Barrera-Saldaña
Pharmacology (2021) 106 (11-12): 588–596.
Published Online: 15 July 2021
... the pharmacokinetics (PK) of metformin, while the role of the two latter can be related to insulin resistance and regulation of adipogenesis. Conclusions: Our results confirm previous genetic associations and point to previously unassociated gene variants for metformin PK and glucose control. © 2021 S. Karger AG...
Pharmacology (2021) 106 (7-8): 384–389.
Published Online: 02 June 2021
... was to explore sufentanil disposition and to propose optimal loading and maintenance doses of sufentanil in ventilated full-term neonates. Methods: Individual sufentanil pharmacokinetic parameters were calculated based on therapeutic drug monitoring data using a 2-compartmental model. Linear regression models...
Ming Yu, Xiaobin Li, Hao Jin, Lu Chen, Nan Wang, Huawei Wang, Ying Cao, Xin Sui, Xue Gao, Hanyue Yang, Wenping Wang
Pharmacology (2021) 106 (7-8): 418–425.
Published Online: 16 April 2021
... diabetes. Very few studies have assessed bioequivalence based on feeding status. This study aimed to assess the pharmacokinetic bioequivalence and safety of nateglinide-containing tablets (0.12 g) in healthy Chinese volunteers under fasting and fed conditions. Methods: The studies were performed in 2017...
Dennis Zetner, Lars Peter Kloster Andersen, Rasmus Alder, Majken Lyhne Jessen, Anders Tolstrup, Jacob Rosenberg
Pharmacology (2021) 106 (3-4): 169–176.
Published Online: 23 March 2021
...Dennis Zetner; Lars Peter Kloster Andersen; Rasmus Alder; Majken Lyhne Jessen; Anders Tolstrup; Jacob Rosenberg Introduction: We aimed to investigate the pharmacokinetic properties and safety of melatonin administered by alternative routes of administration. Methods: This study employed a cross...
Pharmacology (2020) 105 (11-12): 715–718.
Published Online: 27 May 2020
... for crizotinib pharmacokinetics. In order to test whether crizotinib treatment alters CYP3A activity in vivo, mice were treated with 5 and 25 mg/kg crizotinib (p.o.) daily for 14 days. Results showed that crizotinib treatment did not alter CYP3A activity as determined by erythromycin N -demethylation...
Pharmacology (2020) 105 (1-2): 73–78.
Published Online: 02 October 2019
... is a comparison of pharmacokinetics between SC and intravenous (IV) applied nadroparin. Methods: Thirty-eight ventilated ICU patients requiring vasopressor support were randomized into a single dose of nadroparin 3,800 IU (0.4 mL) subcutaneously (SC group) or 1,900 IU (0.2 mL) intravenously (IV group). Anti...
Pharmacology (2019) 104 (1-2): 60–66.
Published Online: 08 May 2019
...Saeed Alqahtani; Thuraya Alzaidi; Mashal Alotaibi; Abdullah Alsultan Objective: This study aimed to assess the population pharmacokinetics of phenytoin in Saudi patients and identify factors affecting therapeutic parameters. Method: A retrospective chart review was performed at King Saud University...
Pharmacology (2018) 102 (5-6): 339–346.
Published Online: 01 November 2018
...Patricia N. Sidharta; Paul L.M. van Giersbergen; Jasper Dingemanse Purpose: To investigate the multiple-dose pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of palosuran, a selective, potent antagonist of the human UT receptor. Methods: This was a double-blind, randomized, placebo...
Pharmacology (2018) 102 (3-4): 154–160.
Published Online: 25 July 2018
... aims to investigate the pharmacokinetic differences between single and combined medication of PAL and HSYA and analyze the interaction of the above effective components in hyperlipidemia rats. Methods: Thirty male SD rats were randomly divided into the control group ( n = 6) and the model group ( n...
Pharmacology (2018) 101 (3-4): 170–175.
Published Online: 02 February 2018
... of the estimates obtained. This project aimed to create an intra-subject variability library of the pharmacokinetic (PK) exposure parameters, area under the curve, and maximum plasma concentration, for probes commonly used in DDI studies. Data from 66 individual DDI studies in healthy subjects relating to 18...
Maria Bianca Abrudan, Dana Maria Muntean, Daniela Saveta Popa, Ana-Maria Gheldiu, Maria Adriana Neag, Laurian Vlase
Pharmacology (2017) 100 (5-6): 301–307.
Published Online: 19 August 2017
...Maria Bianca Abrudan; Dana Maria Muntean; Daniela Saveta Popa; Ana-Maria Gheldiu; Maria Adriana Neag; Laurian Vlase Background/Aims: The aim of this study was to investigate the drug-drug interaction between carvedilol and citalopram based on carvedilol metabolism in vitro and his pharmacokinetics...
Pharmacology (2017) 99 (3-4): 139–143.
Published Online: 05 January 2017
...Maria Bianca Abrudan; Dana Maria Muntean; Ana Maria Gheldiu; Maria Adriana Neag; Laurian Vlase Background/Aims: The effects of multiple-dose bupropion on the pharmacokinetics of single-dose carvedilol were investigated in order to evaluate this possible drug-drug interaction. Methods: A preclinical...
Ioana Todor, Adina Popa, Maria Neag, Dana Muntean, Corina Bocsan, Anca Buzoianu, Laurian Vlase, Ana-Maria Gheldiu, Corina Briciu
Pharmacology (2017) 99 (1-2): 84–88.
Published Online: 05 November 2016
... a possible pharmacokinetic interaction between atomoxetine (ATX), a treatment option for ADHD, and an antidepressant, namely, fluvoxamine (FVX). Methods: Designed as an open-label, non-randomized clinical trial, the study included 2 periods. In period 1 (reference), each subject received ATX 25 mg (single...
Ana-Maria Gheldiu, Adina Popa, Maria Neag, Dana Muntean, Corina Bocsan, Anca Buzoianu, Laurian Vlase, Ioan Tomuta, Corina Briciu
Pharmacology (2016) 98 (3-4): 190–198.
Published Online: 15 June 2016
...Ana-Maria Gheldiu; Adina Popa; Maria Neag; Dana Muntean; Corina Bocsan; Anca Buzoianu; Laurian Vlase; Ioan Tomuta; Corina Briciu Background/Aims: The study aimed at investigating the effects of multiple-dose bupropion (potent inhibitor of CYP2D6) on the pharmacokinetics (PKs) of single-dose...
Pharmacology (2016) 98 (3-4): 111–114.
Published Online: 18 May 2016
...Martine Géhin; Patricia N. Sidharta; Jasper Dingemanse FUTURE-3, a phase III pediatric pharmacokinetic (PK) trial conducted to compare 2 bosentan dosing regimens in 64 patients with pulmonary arterial hypertension, offered the opportunity to compare dried blood spot (DBS)-derived data to plasma...
Ute Blassmann, Anka C. Roehr, Otto R. Frey, Andreas Koeberer, Josef Briegel, Volker Huge, Cornelia Vetter-Kerkhoff
Pharmacology (2016) 98 (1-2): 51–55.
Published Online: 06 April 2016
... curve for 24 h, MIC = minimal inhibitory concentration) is proposed as pharmacokinetic index predictive for efficacy [ 3 ]. Due to the MIC values of pathogens, trough concentrations ≥2 mg/l and/or AUC 24 >160-200 mg*h/l should be achieved to inhibit the growth of 90% of organisms (MIC90...
Pharmacology (2016) 97 (3-4): 107–113.
Published Online: 06 January 2016
...Juanling Zhang; Junbo Zhu; Xingchen Yao; Yabin Duan; Xuejiao Zhou; Meng Yang; Xiangyang Li To investigate the pharmacokinetics of lidocaine hydrochloride metabolized by cytochrome P450 3A4 (CYP3A4) in Chinese Han volunteers living at low altitude (LA) and in native Han and Tibetan Chinese...
Dragana Stokanovic, Valentina N. Nikolic, Sandra S. Konstantinovic, Jelena B. Zvezdanovic, Jelena Lilic, Svetlana R. Apostolovic, Milan Pavlovic, Vladimir S. Zivkovic, Tatjana Jevtovic-Stoimenov, Slobodan M. Jankovic
Pharmacology (2016) 97 (3-4): 101–106.
Published Online: 23 December 2015
... ± 6.6 years, 38 (30.9%) were diagnosed with DM 7.3 ± 7.8 years ago, and 11 patients (8.9%) had atrial fibrillation. Smoking status was categorized as non-smoker or former smoker (62.6%), and current smoker (37.4%). Clopidogrel Pharmacokinetics P-glycoprotein Polymorphism Acute myocardial...